Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer-Reference-Cited by-同舟云学术

Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer

Published:1994-04 Issue:1 Volume:29 Page:45-55
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Magno Lorenzo,Terraneo Fabrizia,Bertoni Filippo,Tordiglione Michele,Bardelli Donata,Rosignoli Maria Teresa,Ciottoli Giovanni Battista

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference54 articles.

1. Phase II study of lonidamine in patients with metastatic breast cancer;Band;Cancer Treat. Rep.,1986

2. Phase II study with lonidamine in advanced Head and Neck (HN) squamous cell carcinoma;Bertetto,1987

3. Le tecniche di irradiazione del collo per la cura di metastasi linfonodali da tumooi solidi del distretto cervico cefalico;Bertoni;Radiol. Med.,1983

4. Pharmacokinetics of lonidamine after oral administration in cancer patients;Besner;Oncology,1984

5. Preliminary results in some tumor systems with indazole-carboxylic acids;Caputo;Chemotherapy,1981

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lonidamine Induced Selective Acidification and De-Energization of Prostate Cancer Xenografts: Enhanced Tumor Response to Radiation Therapy;Cancers;2024-03-31

2. Cancer metabolism and its interplay with pH;pH Deregulation as the Eleventh Hallmark of Cancer;2023

3. Cancer cells co-opt nociceptive nerves to thrive in nutrient-poor environments and upon nutrient-starvation therapies;Cell Metabolism;2022-12

4. Tumoral oxygenation and biodistribution of Lonidamine oxygen microbubbles following localized ultrasound-triggered delivery;International Journal of Pharmaceutics;2022-09

5. circDNMT1 Promotes Malignant Progression of Gastric Cancer Through Targeting miR-576-3p/Hypoxia Inducible Factor-1 Alpha Axis;Frontiers in Oncology;2022-05-30